Key Takeaways
- 3billion will attend the BIO International Convention from June 22-25 to explore AI-powered drug discovery collaborations.
- The company’s AI capabilities are built on genomic and clinical data from over 100,000 patient cases, aiming to identify new therapeutic targets.
- 3billion’s innovative platforms, SAGE and MIN-T, enhance drug candidate design and therapeutic target identification.
3billion Participates in BIO 2026 to Forge Drug Discovery Partnerships
3billion, a South Korean company specializing in AI-powered diagnostics for rare diseases, will participate in the BIO International Convention in San Diego from June 22 to 25. This event, organized by the Biotechnology Innovation Organization (BIO), is recognized as the largest biotechnology industry gathering, attracting over 20,000 stakeholders, including pharmaceutical executives, biotech firms, and investors.
The convention serves as an opportunity for 3billion to engage with global pharmaceutical and biotech companies to discuss potential partnerships in AI-driven drug discovery. The focus will be on collaborative research for novel target discovery and drug candidate development. As the company works to expand its global network of partnerships, these discussions could pave the way for innovative breakthroughs in drug research.
3billion’s drug discovery initiatives leverage extensive genomic and clinical data derived from more than 100,000 patient cases, all collected through its diagnostic services for rare diseases. This robust dataset enables the identification of new therapeutic targets, enhancing the effectiveness of drug candidate development. The company also aims to advance its AI capabilities, further enriching its drug discovery pipeline.
To support these efforts, 3billion utilizes two key platforms: SAGE and MIN-T. SAGE is designed for the identification of novel therapeutic targets, while MIN-T focuses on the creation of drug candidates. By integrating AI with real-world genomic data, these platforms enhance the success rates in the early phases of drug development, significantly improving the overall drug discovery process.
Last year, 3billion showcased its advanced technical capabilities at the international genomic interpretation challenge, CAGI7. The company achieved impressive results, notably outperforming other leading AI models, such as Google DeepMind’s AlphaMissense and Meta’s ESM, in predicting the functionality of genetic variants related to drug response. This performance underscores 3billion’s potential for AI-powered target discovery and drug development.
As CEO Changwon Keum stated, “The combination of patient genomic data collected through rare disease diagnostics and our AI expertise gives us a distinct advantage in drug discovery.” At BIO 2026, 3billion aims to deepen partnerships with global industry leaders, further bridging the gap between rare disease diagnosis and therapeutic development.
The content above is a summary. For more details, see the source article.